ARQL - ArQule, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.53
+0.19 (+2.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close7.34
Open7.40
Bid7.36 x 1200
Ask7.59 x 800
Day's Range7.40 - 7.93
52 Week Range2.23 - 7.93
Volume5,643,443
Avg. Volume1,715,042
Market Cap823.104M
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.53
  • Harry Boxer’s three stocks to watch include Roku
    MarketWatch3 days ago

    Harry Boxer’s three stocks to watch include Roku

    Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule Inc. (ARQL) gained 42 cents to $7.17 on 2.6 million shares traded Tuesday. The move came on no news from the biopharmaceutical company.

  • Benzinga3 days ago

    The Tech Trader's 3 Stocks On The Move

    Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule, Inc. (NASDAQ: ARQL ) gained 42 cents to $7.17 on 2.6 million shares Tuesday. The move, on more than 1/2 times ...

  • Business Wire11 days ago

    ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

    ArQule, Inc. (ARQL) today announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire12 days ago

    ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterContinental New York Barclay in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

  • Business Wire18 days ago

    ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at 3:15 p.m. PT at the Encore Hotel in Las Vegas, NV. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of ARQL earnings conference call or presentation 1-May-19 1:00pm GMT

    Q1 2019 ArQule Inc Earnings Call

  • Arqule Inc (ARQL) Q1 2019 Earnings Call Transcript
    Motley Fool24 days ago

    Arqule Inc (ARQL) Q1 2019 Earnings Call Transcript

    ARQL earnings call for the period ending March 31, 2019.

  • Here's Why ArQule Rose as Much as 12.7% Today
    Motley Fool24 days ago

    Here's Why ArQule Rose as Much as 12.7% Today

    The oncology-focused pharma announced first-quarter 2019 operating results.

  • ArQule (ARQL) Reports Q1 Loss, Misses Revenue Estimates
    Zacks25 days ago

    ArQule (ARQL) Reports Q1 Loss, Misses Revenue Estimates

    ArQule (ARQL) delivered earnings and revenue surprises of -12.50% and -20.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press25 days ago

    ArQule: 1Q Earnings Snapshot

    On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 9 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

  • Benzinga25 days ago

    The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...

  • Business Wire25 days ago

    ArQule Reports First Quarter 2019 Financial Results

    Conference call scheduled today at 9:00 a.m. ET

  • Business Wire25 days ago

    Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration

    ArQule, Inc.’s (ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the initiation of a registrational clinical trial in patients with second-line intrahepatic cholangiocarcinoma (iCCA) in the second half of 2019. “This is an important step forward for derazantinib in China, where the unmet need in iCCA is particularly acute,” said Peter Lawrence, President and COO of ArQule.

  • Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for
    Zackslast month

    Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for

    ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ArQule, Inc. (NASDAQ:ARQL) Insiders Increased Their Holdings
    Simply Wall St.last month

    ArQule, Inc. (NASDAQ:ARQL) Insiders Increased Their Holdings

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares...

  • Business Wirelast month

    ArQule to Report First Quarter 2019 Financial Results on May 1, 2019

    ArQule, Inc. (ARQL) today announced it will report financial results for the first quarter of 2019 before the market opens on Wednesday, May 1, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?
    Zackslast month

    Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?

    Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

  • Business Wire2 months ago

    ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 18th Annual Needham Healthcare Conference on April 9, 2019 at 10:00 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire2 months ago

    ArQule Announces Management Team Changes

    ArQule, Inc. (ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined ArQule in May 2018 and most recently served as Senior Vice President, Head of Strategy, Finance and Communication.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ARQL earnings conference call or presentation 7-Mar-19 2:00pm GMT

    Q4 2018 ArQule Inc Earnings Call

  • Business Wire2 months ago

    ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

  • Business Wire2 months ago

    ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019

    ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California.

  • Can Arqule Stock Continue Rocketing Higher?
    Motley Fool3 months ago

    Can Arqule Stock Continue Rocketing Higher?

    This biotech recently shot up after an experimental treatment helped one patient beat back leukemia.

  • Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today
    Motley Fool3 months ago

    Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today

    Find out how earnings helped these companies' shares rise.

  • Arqule Inc (ARQL) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Arqule Inc (ARQL) Q4 2018 Earnings Conference Call Transcript

    ARQL earnings call for the period ending December 31, 2018.